Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18988163 | SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | December 2024 | June 2025 | Abandon | 6 | 1 | 0 | No | No |
| 18988090 | SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | December 2024 | June 2025 | Abandon | 6 | 1 | 0 | No | No |
| 18913645 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF | October 2024 | April 2025 | Allow | 6 | 1 | 1 | No | No |
| 18805702 | Diagnosis and Treatment of Vitiligo | August 2024 | May 2025 | Allow | 9 | 1 | 1 | Yes | No |
| 18792836 | METHODS OF TREATING BRAIN DISORDERS | August 2024 | May 2025 | Allow | 9 | 1 | 1 | No | No |
| 18776040 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF | July 2024 | January 2025 | Allow | 6 | 2 | 0 | No | No |
| 18743233 | PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER | June 2024 | May 2025 | Allow | 11 | 1 | 0 | No | No |
| 18744484 | NOVEL COMPOSITIONS OF MATTER AND PHARMACEUTICAL COMPOSITIONS | June 2024 | May 2025 | Allow | 11 | 1 | 0 | No | No |
| 18743475 | SARS-COV2 MAIN PROTEASE INHIBITORS | June 2024 | April 2025 | Allow | 11 | 1 | 0 | No | No |
| 18734105 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF | June 2024 | December 2024 | Allow | 6 | 1 | 1 | No | No |
| 18675584 | PIKfyve Inhibitors | May 2024 | June 2025 | Abandon | 12 | 1 | 0 | No | No |
| 18596586 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | March 2024 | January 2025 | Allow | 10 | 1 | 0 | No | No |
| 18584272 | VANADIUM ALKYLIDENE COMPLEX, SYNTHESIS AND USE THEREOF | February 2024 | September 2024 | Allow | 6 | 1 | 1 | No | No |
| 18582218 | IRAK DEGRADERS AND USES THEREOF | February 2024 | October 2024 | Allow | 8 | 0 | 0 | No | No |
| 18430056 | C7 SUBSTITUTED OXYSTEROLS AND METHODS OF USE THEREOF | February 2024 | February 2025 | Allow | 12 | 1 | 0 | Yes | No |
| 18393778 | SUBSTITUTED PYRIDOTRIAZINE COMPOUNDS AND USES THEREOF | December 2023 | October 2024 | Allow | 10 | 1 | 0 | No | No |
| 18530758 | AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS | December 2023 | December 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18496049 | NEW COMPOUNDS AND METHODS OF THEIR MANUFACTURING | October 2023 | August 2024 | Allow | 10 | 0 | 1 | Yes | No |
| 18491524 | METHOD OF TREATING CONDITIONS RELATED TO THE PGI2 RECEPTOR | October 2023 | January 2025 | Allow | 15 | 1 | 0 | No | No |
| 18379576 | Novel Substituted 6,7-Dihydro-5H-Benzo[7]Annulene Compounds, Processes for their Preparation and Therapeutic Uses Thereof | October 2023 | April 2025 | Abandon | 18 | 1 | 1 | No | No |
| 18485093 | COMBINATION THERAPY TO TREAT UREA CYCLE DISORDERS | October 2023 | October 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18480442 | PYRIMIDINE COMPOUND AS JAK KINASE INHIBITOR | October 2023 | August 2024 | Allow | 10 | 1 | 0 | No | No |
| 18372210 | Lithium Conducting Carbon Phosphonitrides from Substituted Cyanophosphine | September 2023 | April 2025 | Allow | 19 | 1 | 0 | No | No |
| 18371722 | NITROXYL DONORS WITH IMPROVED THERAPEUTIC INDEX | September 2023 | August 2024 | Allow | 11 | 1 | 0 | No | No |
| 18370186 | DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT | September 2023 | March 2025 | Allow | 18 | 1 | 1 | No | No |
| 18244659 | HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | September 2023 | December 2024 | Allow | 15 | 1 | 0 | No | No |
| 18241583 | COMPOSITIONS AND METHODS FOR MODULATING HAIR GROWTH | September 2023 | October 2024 | Allow | 13 | 1 | 0 | No | No |
| 18236532 | THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION | August 2023 | July 2024 | Allow | 11 | 1 | 0 | No | No |
| 18354163 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | July 2023 | September 2024 | Allow | 14 | 1 | 0 | No | No |
| 18212375 | HYDROXYNORKETAMINE FOR THE USE IN THE TREATMENT OF DEPRESSION | June 2023 | October 2024 | Allow | 16 | 1 | 1 | No | No |
| 18328267 | Process For Preparing Aminopyrimidine Derivatives | June 2023 | August 2024 | Allow | 15 | 2 | 0 | No | No |
| 18328350 | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF | June 2023 | September 2023 | Allow | 3 | 1 | 0 | Yes | No |
| 18200410 | Methods of Modifying Neuronal Function by Changing Intracellular Magnesium Levels | May 2023 | December 2024 | Abandon | 18 | 0 | 1 | No | No |
| 18196128 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | May 2023 | July 2024 | Allow | 14 | 1 | 1 | No | No |
| 18309992 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | May 2023 | November 2024 | Allow | 18 | 1 | 1 | No | No |
| 18305911 | IRAK DEGRADERS AND USES THEREOF | April 2023 | November 2023 | Allow | 6 | 0 | 0 | No | No |
| 18043178 | SURFACTANTS | February 2023 | May 2025 | Allow | 26 | 1 | 0 | No | No |
| 18113047 | Non-distillative Process for Manufacturing High Purity Amphetamines | February 2023 | December 2024 | Allow | 22 | 1 | 1 | No | No |
| 18018393 | Indole Alkaloid With Fungicidal Effect | January 2023 | July 2025 | Allow | 29 | 0 | 0 | No | No |
| 18093569 | CRYSTALLINE FORMS OF ERAVACYCLINE | January 2023 | December 2024 | Allow | 23 | 1 | 0 | No | No |
| 18004313 | MANUFACTURE OF COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | January 2023 | June 2025 | Allow | 29 | 0 | 0 | No | No |
| 17904464 | NOVEL PHOTOSENSITIZER | December 2022 | June 2025 | Allow | 34 | 0 | 0 | No | No |
| 18075386 | ANALOGS OF CYCLOBENZAPRINE AND AMITRYPTILENE | December 2022 | July 2024 | Allow | 19 | 2 | 1 | Yes | No |
| 18072154 | ORAL FORMULATIONS OF METRONIDAZOLE AND METHODS OF TREATING AN INFECTION USING SAME | November 2022 | November 2024 | Allow | 24 | 2 | 0 | No | Yes |
| 17984011 | COMPOSITIONS AND METHODS TO REDUCE PATHOGENESIS | November 2022 | December 2024 | Abandon | 25 | 0 | 1 | No | No |
| 17997597 | METHODS OF PREPARING SYNTHETIC CANNABICHROMENE AND CANNABICITRAN AND DERIVATIVES THEREOF | October 2022 | December 2024 | Allow | 25 | 0 | 0 | No | No |
| 17997483 | SPIROUREA DERIVATIVES | October 2022 | December 2024 | Allow | 26 | 0 | 0 | No | No |
| 17961020 | Phosphonium Compound, Reagent Kit for Derivatization, Mass Spectrometric Method, and Method for Producing Phosphonium Compound | October 2022 | January 2025 | Allow | 28 | 1 | 1 | Yes | No |
| 17906132 | Compounds and Method of Treating COVID-19 | September 2022 | April 2025 | Allow | 31 | 0 | 0 | No | No |
| 17631114 | WDR5-MYC INHIBITORS | August 2022 | April 2025 | Allow | 39 | 1 | 0 | No | No |
| 17781777 | PROCESS FOR SYNTHESIS OF A 2-(5-ISOXAZOLYL)-PHENOL | June 2022 | January 2025 | Allow | 31 | 0 | 0 | No | No |
| 17756737 | MACROCYCLES COMPRISING A 4-AMIDO-2,4-PENTADIENOATE MOIETY FOR THE TREATMENT OF HYPOXIC CANCERS | June 2022 | May 2025 | Allow | 36 | 1 | 0 | No | No |
| 17780161 | HYDROPYRIDO[1,2-a]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | May 2022 | March 2025 | Allow | 34 | 0 | 0 | No | No |
| 17776950 | IMPROVED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | May 2022 | June 2025 | Allow | 38 | 1 | 0 | Yes | No |
| 17776948 | IMPROVED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | May 2022 | June 2025 | Allow | 38 | 1 | 0 | Yes | No |
| 17775863 | AMORPHOUS PHARMACEUTICAL COMPOSITIONS OF ABIRATERONE ACETATE | May 2022 | June 2025 | Allow | 37 | 1 | 0 | No | No |
| 17773135 | OXADIAZOLINE COMPOUND OR SALTS THEREOF, AGRICULTURAL AND HORTICULTURAL FUNGICIDE CONTAINING SAID COMPOUND, AND METHOD FOR USING SAME | April 2022 | April 2025 | Allow | 36 | 1 | 0 | No | No |
| 17773136 | PHARMACEUTICAL COMPOUNDS | April 2022 | June 2025 | Allow | 38 | 1 | 0 | No | No |
| 17770083 | PROCESS FOR PREPARATION OF THIOPHOSPHORYL CHLORIDE AND ACEPHATE | April 2022 | January 2025 | Allow | 33 | 1 | 1 | Yes | No |
| 17719412 | PULMONARY HYPERTENSION TREATMENT | April 2022 | November 2024 | Allow | 31 | 1 | 1 | No | No |
| 17768354 | PHOSPHORAMIDITE ACTIVATOR | April 2022 | September 2024 | Allow | 29 | 0 | 0 | No | No |
| 17767034 | SPIRO RING-CONTAINING QUINAZOLINE COMPOUNDS | April 2022 | June 2025 | Allow | 38 | 1 | 0 | No | No |
| 17762793 | ALDOKETO REDUCTASE INHIBITORS AND USES THEREOF | March 2022 | April 2025 | Allow | 37 | 1 | 0 | No | No |
| 17697089 | Method of Regulating Immunity in the Intestines | March 2022 | October 2024 | Allow | 31 | 2 | 1 | No | No |
| 17642092 | HETEROBICYCLIC CARBOXAMIDES AND USES THEREOF | March 2022 | June 2025 | Allow | 39 | 1 | 0 | No | No |
| 17640697 | OIL LIQUID FUNGICIDAL COMPOSITIONS | March 2022 | June 2025 | Allow | 40 | 1 | 0 | No | No |
| 17636331 | HETEROCYCLIC THR-B RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREFOR | February 2022 | March 2025 | Allow | 37 | 1 | 0 | Yes | No |
| 17635491 | CRYSTALLINE FORM OF L-GLUFOSINATE AMMONIUM SALT AND PROCESS FOR PRODUCTION THEREOF | February 2022 | December 2024 | Allow | 34 | 1 | 1 | Yes | No |
| 17635462 | Preparation Method for Oxazepine Compound | February 2022 | May 2025 | Allow | 39 | 1 | 0 | No | No |
| 17634174 | COMPOUNDS SUITABLE FOR THE TREATMENT AND PROPHYLAXIS OF MUSCLE WASTING AND OTHER CONDITIONS | February 2022 | February 2025 | Allow | 36 | 0 | 0 | No | No |
| 17629955 | UREA COMPOUND FOR ANTAGONIZING LPA1 RECEPTOR | January 2022 | January 2025 | Allow | 36 | 0 | 0 | Yes | No |
| 17627915 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS | January 2022 | February 2025 | Allow | 37 | 0 | 0 | No | No |
| 17563913 | COMPOUNDS AND METHODS FOR INHIBITING JAK | December 2021 | January 2025 | Allow | 37 | 1 | 0 | No | No |
| 17621705 | HIGH YIELD, ECO-FRIENDLY RECYCLING METHOD OF POLYLACTIC ACID USING SUPERCRITICAL OR DENSE GAS CARBON DIOXIDE | December 2021 | November 2024 | Allow | 35 | 0 | 0 | No | No |
| 17619739 | NEW COMPOSITION CONTAINING BRANCHED-CHAIN AMINO ACIDS | December 2021 | November 2024 | Allow | 35 | 1 | 0 | No | No |
| 17611977 | OXADIAZOLE COMPOUNDS OR SALTS THEREOF, AGROHORTICULTURAL FUNGICIDES CONTAINING THE COMPOUNDS, AND METHODS OF USING THE SAME | November 2021 | August 2024 | Allow | 33 | 0 | 0 | No | No |
| 17611093 | CANNABINOIDS AND USES THEREOF | November 2021 | December 2024 | Allow | 37 | 0 | 1 | No | No |
| 17509769 | 5,6,7,7a-Tetrahydrocyclopenta[f]pyrido[1,2-h][1,7]naphthyridin-11(4bH)-one Compounds and Methods of Use | October 2021 | August 2024 | Allow | 33 | 0 | 0 | No | No |
| 17605111 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | October 2021 | February 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17602803 | INHIBITORS OF TRPC6 | October 2021 | August 2024 | Allow | 34 | 0 | 0 | No | No |
| 17602758 | PIPERAZINE AMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | October 2021 | December 2024 | Allow | 38 | 1 | 0 | No | No |
| 17599391 | Pharmaceutical Combination Formulations Comprising Tizanidine, Resveratrol and Piperine | September 2021 | May 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17599341 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR USE AS PROTEOLYSIS TARGETING CHIMERA LIGANDS | September 2021 | October 2024 | Allow | 36 | 1 | 0 | Yes | No |
| 17598569 | PANTETHENOYLCYSTEINE DERIVATIVES AND USES THEREOF | September 2021 | November 2024 | Allow | 38 | 1 | 1 | No | No |
| 17598271 | TREATMENT OF HIDRADENITIS SUPPURATIVA WITH TAPINAROF COMPOSITIONS | September 2021 | April 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17442022 | METHODS FOR TREATING COLORECTAL CANCER | September 2021 | April 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17437519 | COMPOUNDS HAVING EXCITED STATE INTRAMOLECULAR PROTON TRANSFER (ESIPT) CHARACTER FOR USE IN TREATING AND/OR PREVENTING SUNBURN AND/OR PREVENTING U.V. DAMAGE | September 2021 | December 2024 | Allow | 39 | 0 | 1 | No | No |
| 17593110 | POLYMORPHS AND COCRYSTALS OF A CARDIAC TROPONIN ACTIVATOR | September 2021 | June 2024 | Allow | 33 | 0 | 0 | No | No |
| 17436231 | USE OF CAPRYLIC AND CAPRIC TRIGLYCERIDES FOR THE TREATMENT OF A DISEASE OR CONDITION MEDIATED BY FILAGGRIN OR COLLAGEN DEFICIENCY | September 2021 | August 2024 | Allow | 35 | 0 | 0 | No | No |
| 17433204 | CYAN COLORED CURABLE COMPOSITION | August 2021 | March 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17432838 | PROTEIN AND/OR PEPTIDE MODIFICATION MOLECULE | August 2021 | March 2025 | Allow | 43 | 1 | 1 | No | No |
| 17407146 | LUMINESCENT PARTICLE AND COMPOUND | August 2021 | August 2024 | Allow | 36 | 0 | 0 | No | No |
| 17396312 | AZAINDOLE COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | August 2021 | January 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17428730 | 3-AMINO-2-[2-(ACYLAMINO)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE AS CSNK1 INHIBITORS | August 2021 | October 2024 | Allow | 38 | 1 | 0 | No | No |
| 17421336 | STEROID COMPOUND, AND USE THEREOF AND PREPARATION METHOD THEREFOR | July 2021 | April 2025 | Allow | 45 | 1 | 1 | No | No |
| 17418858 | GEL COMPOSITION WITH AN ANAESTHETIC EFFECT OF SHORT AND LONG TERM DURATION | June 2021 | February 2025 | Allow | 44 | 1 | 1 | No | No |
| 17418019 | N-(4-(OXAZOL-5-YL)PHENYL) CHROMANE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS STIMULATORS OF THE PRODUCTION OF RETINAL PRECURSOR CELLS FOR THE TREATMENT OF NEURORETINAL DISEASES | June 2021 | September 2024 | Allow | 39 | 1 | 0 | Yes | No |
| 17415899 | CARBONIC ANHYDRASE INHIBITORS AND ANTIBIOTICS AGAINST MULTIDRUG RESISTANT BACTERIA | June 2021 | March 2025 | Allow | 45 | 2 | 1 | Yes | No |
| 17311964 | BI-FUNCTIONAL NANOHYBRIDS | June 2021 | May 2025 | Abandon | 47 | 0 | 2 | No | No |
| 17311433 | ANTIBACTERIAL COMPOUNDS AND USES THEREOF | June 2021 | March 2025 | Allow | 46 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner VAJDA, KRISTIN ANN.
With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 33.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner VAJDA, KRISTIN ANN works in Art Unit 1622 and has examined 1,000 patent applications in our dataset. With an allowance rate of 88.4%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 17 months.
Examiner VAJDA, KRISTIN ANN's allowance rate of 88.4% places them in the 65% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by VAJDA, KRISTIN ANN receive 1.00 office actions before reaching final disposition. This places the examiner in the 12% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by VAJDA, KRISTIN ANN is 17 months. This places the examiner in the 96% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +11.1% benefit to allowance rate for applications examined by VAJDA, KRISTIN ANN. This interview benefit is in the 49% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 42.3% of applications are subsequently allowed. This success rate is in the 93% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 80.3% of cases where such amendments are filed. This entry rate is in the 96% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 91.7% of appeals filed. This is in the 82% percentile among all examiners. Of these withdrawals, 72.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 52.5% are granted (fully or in part). This grant rate is in the 65% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 7.1% of allowed cases (in the 93% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.3% of allowed cases (in the 67% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.